Tags: Drug.

Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator and as of October 2009 it is being investigated in Phase I and II clinical trials for the treatment of chronic lymphocytic leukemia. The drug is a chimeric antibody from Macaca irus and Homo sapiens.

ATC prefix
none
FDA UNII code
8Z13S29R5A

Loading...

This page contains content from the copyrighted Wikipedia article "Lumiliximab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.